Analyst Price Target is $7.25
▲ +935.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Precision BioSciences in the last 3 months. The average price target is $7.25, with a high forecast of $17.00 and a low forecast of $2.00. The average price target represents a 935.71% upside from the last price of $0.70.
Current Consensus is
The current consensus among 4 investment analysts is to hold stock in Precision BioSciences. This rating has held steady since August 2022, when it changed from a Buy consensus rating.
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.